Clinical Trials Browser

Terminated × OTHER × pembrolizumab × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03386357 2026-03-12

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Terminated

115 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT04777851 2026-03-09

REPLACE

Phase 3 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03237572 2026-02-09

Breast-48

Phase 1 Terminated

13 enrolled 10 charts

Breast Neoplasms

NCT04166734 2026-02-04

MESO-PRIME

Phase 1 Terminated

5 enrolled 13 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03436056 2026-01-29

PRIMING

Phase 1 Terminated

2 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04557007 2026-01-29

Oncomabs

NSCLC

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT02819752 2026-01-21

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Phase 2 Terminated

6 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03260504 2025-12-08

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 1 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03595683 2025-12-08

Pembrolizumab and EDP1503 in Advanced Melanoma

Phase 2 Terminated

8 enrolled 10 charts

Melanoma

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2 Terminated

34 enrolled 18 charts

Melanoma

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Phase 2 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT05036681 2025-09-17

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 8 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT03307759 2025-09-15

SABRseq

Phase 1 Terminated

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2 Terminated

52 enrolled 15 charts

Glioblastoma

NCT02892201 2025-07-29

Pembrolizumab in HNSCC With Residual Disease After Radiation

Phase 2 Terminated

9 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Phase 2 Terminated

Meningeal Carcinomatosis

NCT04904185 2025-07-25

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Phase 1 Terminated

8 enrolled 8 charts

Melanoma

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05059470 2025-07-08

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Phase 2 Terminated

Thyroid Diseases

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms

NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Phase 2 Terminated

3 enrolled 7 charts

Adrenocortical Carcinoma

NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Phase 1/2 Terminated

7 enrolled 11 charts

Melanoma

NCT06140407 2025-06-05

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Phase 2 Terminated

Lung Neoplasms

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Phase 2 Terminated

31 enrolled 15 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03286114 2025-05-11

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Phase 1 Terminated

16 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 1/2 Terminated

7 enrolled 15 charts

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03016091 2025-02-18

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Phase 2 Terminated

18 enrolled 9 charts

Hemangiopericytoma, Meningioma

NCT05191472 2025-01-15

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Phase 2 Terminated

3 enrolled 5 charts

Multiple Myeloma

NCT04856176 2025-01-01

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung